全文获取类型
收费全文 | 22130篇 |
免费 | 2713篇 |
国内免费 | 364篇 |
专业分类
耳鼻咽喉 | 260篇 |
儿科学 | 296篇 |
妇产科学 | 219篇 |
基础医学 | 822篇 |
口腔科学 | 222篇 |
临床医学 | 1593篇 |
内科学 | 3138篇 |
皮肤病学 | 127篇 |
神经病学 | 300篇 |
特种医学 | 1177篇 |
外国民族医学 | 44篇 |
外科学 | 2091篇 |
综合类 | 2337篇 |
预防医学 | 791篇 |
眼科学 | 145篇 |
药学 | 1002篇 |
9篇 | |
中国医学 | 557篇 |
肿瘤学 | 10077篇 |
出版年
2024年 | 47篇 |
2023年 | 456篇 |
2022年 | 921篇 |
2021年 | 1214篇 |
2020年 | 1082篇 |
2019年 | 1145篇 |
2018年 | 1051篇 |
2017年 | 882篇 |
2016年 | 899篇 |
2015年 | 895篇 |
2014年 | 1539篇 |
2013年 | 1467篇 |
2012年 | 1312篇 |
2011年 | 1406篇 |
2010年 | 1195篇 |
2009年 | 1114篇 |
2008年 | 998篇 |
2007年 | 1178篇 |
2006年 | 984篇 |
2005年 | 826篇 |
2004年 | 659篇 |
2003年 | 574篇 |
2002年 | 465篇 |
2001年 | 429篇 |
2000年 | 336篇 |
1999年 | 307篇 |
1998年 | 269篇 |
1997年 | 217篇 |
1996年 | 155篇 |
1995年 | 135篇 |
1994年 | 110篇 |
1993年 | 78篇 |
1992年 | 103篇 |
1991年 | 80篇 |
1990年 | 63篇 |
1989年 | 59篇 |
1988年 | 75篇 |
1987年 | 62篇 |
1986年 | 44篇 |
1985年 | 78篇 |
1984年 | 57篇 |
1983年 | 51篇 |
1982年 | 48篇 |
1981年 | 35篇 |
1980年 | 28篇 |
1979年 | 21篇 |
1978年 | 10篇 |
1977年 | 19篇 |
1976年 | 10篇 |
1975年 | 9篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
《Cancer radiothérapie》2022,26(4):611-615
In order to provide more convenient irradiation regimens for patient comfort, radiation facility organization and health expenses, new hypofractionated protocols have been evaluated. Moderately (dose/fraction: 2.3 to 3 Gy), then ultra (dose/fraction: 5.2 to 6.1 Gy) hypofractionated irradiations were first validated. The current question is: is it possible to go forward using extreme hypofractionated regimens (EHR) based on 1 to 3 fractions. Different irradiation techniques are under investigation. However, brachytherapy remains the smartest way to deliver a high dose in a small volume. We report prospective and retrospective study results which evaluated EHR for breast and prostate brachytherapy. While oncological outcome and toxicity profile appear extremely encouraging for low-risk breast cancer after a 1 to 4 fractions (6.25 to 20 Gy/fraction), the use of a single fraction of 19 to 23 Gy appears debatable for prostate cancer. Brachytherapy represents an emblematic example of EHR but longer follow-up and more mature results are awaited in order to specify the right indications and refine the EQD2 calculation method including new biological and technical factors. 相似文献
2.
《Pancreatology》2022,22(8):1175-1180
BackgroundHepatic steatosis has been described as a common finding in adults following total pancreatectomy with islet autotransplantation (TPIAT) but it is unknown if this occurs in children and adolescents.ObjectivesTo define the frequency of post-TPIAT hepatic steatosis in a sample of children and adolescents and to identify clinical predictors of incident steatosis post-TPIAT.MethodsIn this prospective study, consecutive participants at least 1-month post-TPIAT underwent a liver MRI with proton density fat fraction (PDFF) and blood draw at our pediatric academic medical center between April 2021 and January 2022. Comparison clinical pre-TPIAT liver MRI or ultrasound and insulin use and graft function data were extracted from the medical record. T-tests were used for the comparison of means across continuous variables between participants with and without post-TPIAT steatosis.ResultsA total of 20 participants (mean: 13 ± 4 years; 12 female) were evaluated. Mean liver PDFF at research MRI was 7.4 ± 6.2% (range: 2–25%). Seven participants (35%) had categorical hepatic steatosis (PDFF>5%) post-TPIAT, five of whom had pre-TPIAT steatosis, reflecting a 13% (2/15; 95% CI: 2–40%) incidence of post-TPIAT steatosis. Participant characteristics were not significantly different between subgroups with and without post-TPIAT steatosis. Mean PDFF at research MRI was not different between graft function subgroups (7.5% optimal/good vs. 7.3% marginal/failure; p = .96).ConclusionOur study shows a moderate prevalence but low incidence of hepatic steatosis in a small sample of children and adolescents post-TPIAT. This study raises questions about a causal relationship between TPIAT and hepatic steatosis. 相似文献
3.
Adjuvant irradiation is the standard treatment after breast conservative surgery. Normofractionated regimen with an overall treatment time of 5 to 6 weeks is often considered as a limiting factor for irradiation compliance. In order to answer this issue, moderate and more recently extreme hypofractionated protocols appeared. We report here oncological outcomes and toxicity of hypofractionated breast irradiation. After defining the frame of moderate and extreme hypofractionated breast irradiations based on overall treatment time, patient selection criteria were listed. According to their levels of proof, the results of moderate and extreme hypofractionated breast irradiation were analysed. Overall treatment time for moderate hypofractionated breast irradiation ranged from 3 to 4 weeks, while for extreme hypofractionated breast irradiation, it was less than 1 week. For moderate hypofractionated breast irradiation, whole breast irradiation was currently performed with or without lymph node irradiation. Moderate hypofractionated breast irradiation has proven to be as safe and as efficient as normofractionated breast irradiation with level IA evidence. For extreme hypofractionated breast irradiation, phase III randomized trials confirmed that accelerated partial breast irradiation was non-inferior in terms of local control compared to normofractionated whole breast irradiation (with external beam radiation therapy and multicatheter brachytherapy), with similar acute and late toxicity. While the use of intraoperative breast irradiation remains under debate, new very accelerated partial breast irradiation (overall treatment time not exceeding 2 days) protocols emerged with encouraging results. Accelerated partial breast irradiation is warranted for extreme hypofractionated breast irradiation and is indicated for low-risk breast cancers. Moderate and extreme hypofractionated breast irradiation regimens are validated and can be routinely proposed according to patient selection criteria. 相似文献
4.
5.
6.
7.
8.
9.
10.
This retrospective study aimed to evaluate radiation-induced pneumonitis (RIP) and a related condition that we define in this report—prolonged minimal RIP (pmRIP)—after stereotactic body radiotherapy (SBRT) for Stage I primary lung cancer in patients with chronic obstructive pulmonary disease (COPD). We assessed 136 Stage I lung cancer patients with COPD who underwent SBRT. Airflow limitation on spirometry was classified into four Global Initiative for Chronic Obstructive Lung Disease (GOLD) grades, with minor modifications: GOLD 1 (mild), GOLD 2 (moderate), GOLD 3 (severe) and GOLD 4 (very severe). On this basis, we defined two subgroups: COPD-free (COPD −) and COPD-positive (COPD +). There was no significant difference in overall survival or cause-specific–survival between these groups. Of the 136 patients, 44 (32%) had pmRIP. Multivariate analysis showed that COPD and the Brinkman index were statistically significant risk factors for the development of pmRIP. COPD and the Brinkman index were predictive factors for pmRIP, although our findings also indicate that SBRT can be tolerated in early lung cancer patients with COPD. 相似文献